Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...

Antibody therapies are a type of biologic. They are typically monoclonal antibodies selected to bind to a particular protein (often a cell-surface protein), and produced using recombinant DNA ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc?RIIb, which are broadly present across B cell lineage, to inhibit the activity of ...

Different types of antibodies are produced by your immune system. These five antibodies help fight disease by detecting viruses, bacteria, and other pathogens (disease-causing microorganisms) and ...

Anti-SS-A and anti-SS-B are autoantibodies (antibodies that mistakenly attack the body's own tissue). Elevated levels of these autoantibodies are strongly associated with Sjögren’s disease, in which ...

Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection. But Scripps Research scientists have now discovered that for some HIV ...

Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection. Scientists at Scripps Research have now made a new discovery for some ...

Patients using monoclonal antibody treatment vs standard of care had a significantly lower annualized exacerbation rate (RR, 0.82). Treating eosinophilic chronic obstructive pulmonary disease (COPD) ...

A look at cancer cells: Thanks to an innovative method of super-resolution microscopy, researchers observed with molecular resolution in 3D how therapeutic antibodies attack and alter B cells ...

However, applying this approach to antibodies has proven more challenging, primarily due to the high degree of variability inherent in these proteins. To overcome that limitation, MIT researchers have ...